1. Home
  2. GAP vs GLSI Comparison

GAP vs GLSI Comparison

Compare GAP & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAP
  • GLSI
  • Stock Information
  • Founded
  • GAP 1969
  • GLSI 2006
  • Country
  • GAP United States
  • GLSI United States
  • Employees
  • GAP N/A
  • GLSI N/A
  • Industry
  • GAP
  • GLSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • GAP
  • GLSI Health Care
  • Exchange
  • GAP NYSE
  • GLSI Nasdaq
  • Market Cap
  • GAP N/A
  • GLSI 131.1M
  • IPO Year
  • GAP N/A
  • GLSI 2020
  • Fundamental
  • Price
  • GAP $22.31
  • GLSI $9.85
  • Analyst Decision
  • GAP Buy
  • GLSI Strong Buy
  • Analyst Count
  • GAP 11
  • GLSI 1
  • Target Price
  • GAP $28.82
  • GLSI $39.00
  • AVG Volume (30 Days)
  • GAP 12.8M
  • GLSI 37.8K
  • Earning Date
  • GAP 05-29-2025
  • GLSI 05-20-2025
  • Dividend Yield
  • GAP 2.96%
  • GLSI N/A
  • EPS Growth
  • GAP 28.67
  • GLSI N/A
  • EPS
  • GAP 2.30
  • GLSI N/A
  • Revenue
  • GAP $15,161,000,000.00
  • GLSI N/A
  • Revenue This Year
  • GAP $1.98
  • GLSI N/A
  • Revenue Next Year
  • GAP $1.64
  • GLSI N/A
  • P/E Ratio
  • GAP $9.70
  • GLSI N/A
  • Revenue Growth
  • GAP 1.07
  • GLSI N/A
  • 52 Week Low
  • GAP $16.99
  • GLSI $8.06
  • 52 Week High
  • GAP $30.75
  • GLSI $18.75
  • Technical
  • Relative Strength Index (RSI)
  • GAP N/A
  • GLSI 50.03
  • Support Level
  • GAP N/A
  • GLSI $9.59
  • Resistance Level
  • GAP N/A
  • GLSI $10.10
  • Average True Range (ATR)
  • GAP 0.00
  • GLSI 0.54
  • MACD
  • GAP 0.00
  • GLSI 0.03
  • Stochastic Oscillator
  • GAP 0.00
  • GLSI 43.28

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: